Paolo Ascierto

New Capabilities

Key author of the Phase 3 study

Adding an oral histone deacetylase (HDAC) inhibitor to nivolumab cut the risk of melanoma progression or death by 27% in a 404-patient Phase 3 trial. Median progression-free survival was 11.7 months with the combination and 7.4 months with nivolumab alone, according to results presented at the European Society for Medical Oncology congress in Madrid.

Updated Oct 30